The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Our evolving understanding of high-risk myeloma & the value of novel agents
In this video, Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the evolving understanding of high-risk myeloma, highlighting the recognition of mutational changes in TP53 and biallelic changes as key factors. Dr Ramasamy also discusses the potential of BCMA- and GPRC5D-targeting agents to treat high-risk patients, aiming to achieve deeper and longer remissions. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI generated)
High-risk myeloma continues to remain a challenge. We now have a new settled status of what high-risk is and that recognizes mutational changes in TP53. It also recognizes biallelic changes which was not previously recognized. And thankfully this gives us a new cohort of patients that we’ll be targeting in clinical trials. In the RADAR trial that we’re running in the UK, we’re already targeting those double-hit patients as a high-risk cohort of patients and we’re treating them with continuous multi-agent chemotherapy to induce remission and maintain remission for long periods of time...
High-risk myeloma continues to remain a challenge. We now have a new settled status of what high-risk is and that recognizes mutational changes in TP53. It also recognizes biallelic changes which was not previously recognized. And thankfully this gives us a new cohort of patients that we’ll be targeting in clinical trials. In the RADAR trial that we’re running in the UK, we’re already targeting those double-hit patients as a high-risk cohort of patients and we’re treating them with continuous multi-agent chemotherapy to induce remission and maintain remission for long periods of time. But what is really exciting is the data that we’ve seen with BCMA-targeted agents and the data we’ve seen with GPRC5D-targeted agents. Those agents are probably going to be propelled into the high-risk setting in the newly diagnosed patient population. And we would like to see deeper remissions and longer remissions in high-risk patients with these new agents.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
GSK: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Sanofi: Consultancy, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau; Adaptive Biotech: Consultancy, Speakers Bureau; Johnson and Johnson: Consultancy, Speakers Bureau; Menarini Stemline: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Recordati rare Disease: Consultancy, Speakers Bureau.
